Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is caused by mutations in the PKD1 or PKD2 genes, which encode polycystins 1 and 2. Patients develop renal cysts associated with a progressive decline in kidney function, ultimately leading to end-stage renal disease in approximately one third of cases. ADPKD is also characterized by early-onset hypertension and cardiovascular complications, notably intracranial aneurysms.
This phenotype is related to abnormal polycystin function in the primary cilia of renal epithelial and vascular endothelial cells, resulting in impaired mechanotransduction of shear stress induced by urinary and blood flow and subsequent alterations in multiple cellular functions. Experimental studies have suggested that stimulation of dopamine receptor type 5 (DR5) may restore endothelial mechanosensitivity. This hypothesis is supported by our preliminary results showing that local administration of dopamine improves endothelial function in patients with ADPKD through restoration of nitric oxide (NO) release in response to increased blood flow.
Consistent with these findings, the IMPROVE-PKD study recently demonstrated similar beneficial effects on endothelial function and hemodynamics using rotigotine, a dopamine agonist administered via transdermal patches for two months at a low dose (4 mg/24 h). Dopaminergic stimulation may also prevent renal abnormalities related to polycystin deficiency. We therefore hypothesize that rotigotine could slow the progression of ADPKD at both the renal and cardiovascular levels.
This phase 2 study aims to evaluate the long-term tolerability of rotigotine in patients with ADPKD and to collect preliminary data on its effects on renal outcomes.

Start Date12 May 2026

Sponsor / Collaborator-

CTIS2025-521172-64-00

/ Not yet recruitingPhase 2

Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed Rotigotine 12 mg/24 h transdermal patch in patients with Parkinson’s disease

Start Date05 Jan 2026

Sponsor / Collaborator

Luye Pharma Switzerland AG

CTR20254138

/ CompletedNot Applicable

罗替高汀贴片在中国受试者外用条件下单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计空腹给药人体生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-period, two-sequence crossover design bioequivalence study of rotigotine patch administered on an empty stomach in Chinese subjects under topical conditions

本试验旨在研究单次空腹使用杭州朱养心药业有限公司研制、生产的罗替高汀贴片﹝4.5 mg/10 cm2，（释药量2 mg/24 h）﹞的药代动力学特征；以UCB Pharma S.A.持证、LTS Lohmann Therapie-Systeme AG生产的罗替高汀贴片〔Neupro®/优普洛®，4.5 mg/10 cm2（释药量2 mg/24 h）〕为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性，并考察受试制剂和参比制剂在用药过程中的安全性、粘附性和皮肤刺激性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of a single fasting dose of a rotigotine patch (4.5 mg/10 cm², 2 mg/24 h release) developed and produced by Hangzhou Zhuyangxin Pharmaceutical Co., Ltd. Using a rotigotine patch (Neupro®, 4.5 mg/10 cm², 2 mg/24 h release) licensed by UCB Pharma S.A. and produced by LTS Lohmann Therapie-Systeme AG as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate their bioequivalence in humans. The safety, adhesion, and skin irritation of the test and reference preparations during use were also investigated.

Start Date22 Oct 2025

Sponsor / Collaborator

Hangzhou Zhuyangxin Pharmaceutical Co. Ltd.

100 Clinical Results associated with Rotigotine

100 Translational Medicine associated with Rotigotine

100 Patents (Medical) associated with Rotigotine

708

Literatures (Medical) associated with Rotigotine

24 Feb 2026·JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Restless Legs Syndrome

Review

Author: Wipper, Benjamin ; Winkelman, John W.

Importance:

Restless legs syndrome (RLS) is a sleep-related movement disorder that affects approximately 3% of US adults to a clinically significant extent and can cause substantial sleep disturbance.

Observations:

Restless legs syndrome is characterized by an overwhelming urge to move the limbs, typically the legs, often accompanied by unpleasant limb sensations (eg, achiness, tingling). Symptoms, provoked by immobility, are relieved while moving and are typically present or most severe in the evening or at night. Restless legs syndrome symptoms may lead to difficulty falling asleep, staying asleep, or returning to sleep. According to population-based studies, approximately 8% of US adults experience RLS symptoms of any frequency annually and 3% experience moderately or severely distressing symptoms at least twice weekly. Patients with RLS have impaired quality of life and elevated rates of cardiovascular disease (29.6% with coronary artery disease, stroke, or heart failure), depression (30.4%), and suicidal ideation or self-harm (0.35 cases/1000 person-years). Restless legs syndrome is common among patients with multiple sclerosis (27.5%), end-stage kidney disease (24%), and iron deficiency anemia (23.9%); during pregnancy and especially in the third trimester (22%); with peripheral neuropathy (eg, diabetic, idiopathic; 21.5%); and with Parkinson disease (20%). Other risk factors include family history of RLS, northern European descent, female sex (2:1 vs male sex), and older age (RLS prevalence of 10% in adults ≥65 years). Restless legs syndrome is diagnosed based on clinical history; polysomnography is not recommended for diagnosis. Iron supplementation with ferrous sulfate (325-650 mg daily or every other day) or intravenous iron (1000 mg) should be initiated for serum ferritin level less than or equal to 100 ng/mL or transferrin saturation less than 20%. If possible, medications associated with RLS, including serotonergic antidepressants, dopamine antagonists, and centrally acting H1 antihistamines (eg, diphenhydramine), should be discontinued. Gabapentinoids (eg, gabapentin, gabapentin enacarbil, pregabalin) are first-line pharmacologic therapy. In randomized clinical trials, approximately 70% of patients treated with gabapentinoids had much or very much improved RLS symptoms vs approximately 40% with placebo ( P &lt; .001). Dopamine agonists (eg, ropinirole, pramipexole, rotigotine) are no longer recommended as first-line medications due to the risk of augmentation, an iatrogenic worsening of RLS symptoms, which has an annual incidence of 7% to 10% with these medications. Patients who do not improve with first-line treatment or have augmented RLS often benefit from low-dose opioids (eg, methadone 5-10 mg daily).

Conclusions and Relevance:

Restless legs syndrome affects approximately 3% of adults and can have negative effects on sleep and quality of life. Initial management includes cessation of exacerbating medications, as well as iron supplementation for patients with low-normal iron indices. If medication therapy is indicated, gabapentinoids are first-line treatment.

01 Jan 2026·Case reports in dermatological medicine

Autoimmunity to Collagen XVII (BP180-Ag2) in Pemphigoid Associated With Parkinson's Disease.

Article

Author: Herrera-Esparza, Rafael ; Avalos-Diaz, Esperanza ; Ornelas-Ramírez, Ingrid-Gabriela ; Cid-Puente, Ricardo ; Bollain-Y-Goytia, Juan-José ; González-Herrera, Lorena

The association between Parkinson's disease and autoimmune disease is rare; in our population, there is 1 case per 10,000 inhabitants. Bullous pemphigoid has a much lower incidence, and consequently, the association of Parkinson's disease and bullous pemphigoid is rarer. We present the case of an 84-year-old patient with a 16-year history of Parkinson's disease, treated with rotigotine, levodopa, and carbidopa. The patient spontaneously developed tense blisters that spread to the trunk and extremities within 1 year of the first occurrence of dermatological symptoms. A lesional biopsy revealed a subepidermal blister with inflammatory infiltrates, and immunofluorescent evaluation of the biopsy revealed immune deposits of IgG at the basement membrane. The serum displayed antibasement membrane autoantibodies that reacted with monkey esophagus tissue, and immunofluorescence revealed that the patient was positive for antineuronal antibodies that reacted with mouse brain tissue. The molecular reactivity of the serum and fluid obtained from a bulla was positive for the BP180-Ag2 antigen, as determined by ELISA. Additionally, six Parkinson's serum samples without pemphigoid disease were tested as controls, and only one serum sample was reactive to BP180-Ag2. A critical review of the possible pathogenic mechanisms of this rare association is discussed.

01 Jan 2026·Clinical parkinsonism & related disorders

Rotigotine and parkinsonism-hyperpyrexia syndrome

Article

Author: Fujiwara, Eiko ; Watanabe, Shohei ; Kasama, Shuhei ; Yamanaka, Daisuke ; Morishita, Hosho ; Hasuike, Ayano ; Igeta, Masataka ; Kimura, Takashi ; Yagi, Koji

Introduction:

Parkinsonism-hyperpyrexia syndrome (PHS) is a potentially fatal complication of Parkinson's disease (PD) often triggered by antiparkinsonian medication discontinuation or reduction. Rotigotine, a transdermal dopamine agonist, provides continuous drug delivery and can be administered even when oral administration is difficult. However, the association between rotigotine use and development of PHS remains unclear.

Methods:

We retrospectively reviewed 166 episodes of emergency hospitalization for PD at Hyogo Medical University Hospital (2010-2024). After excluding 19 episodes with insufficient data, 147 were analyzed. Thirty episodes met the diagnostic criteria for PHS (PHS group), and 117 episodes did not (non-PHS group). Clinical characteristics, antiparkinsonian medications, and precipitating events during hospitalization were assessed. A multivariable logistic regression analysis was performed using age, sex, disease duration, and rotigotine administration as covariates.

Results:

The PHS group had a shorter disease duration, lower modified Hoehn and Yahr stages, and a lower levodopa equivalent dose than the non-PHS group. Poor medication compliance was the most common precipitating factor among PHS cases (n = 11, 36.7%). Rotigotine was administered in five PHS and 41 non-PHS episodes. In the multivariable analysis, age was significantly negatively associated with the development of PHS (odds ratio [OR], 0.894; 95% confidence interval [CI], 0.840-0.952; p = 0.0005). And rotigotine administration showed a tendency to suppress the development of PHS (OR, 0.353; 95% CI, 0.121-1.031; p = 0.0569).

Conclusion:

Although not statistically significant, rotigotine use tends to be associated with a lower incidence of PHS. Maintaining good medication adherence is critical for preventing PHS, and we consider that rotigotine may be a useful therapeutic option.

News (Medical) associated with Rotigotine

15 Sep 2025

·www.fiercepharma.com

BMS sells controlling stake in historic US-China pharmaceutical joint venture

Bristol Myers Squibb originally linked up with China’s Sinopharm Foreign Trade to establish Sino-American Shanghai Squibb Pharmaceuticals as the first U.S.-China pharmaceutical joint venture back in 1982. More than 40 years after establishing the first U.S. pharmaceutical joint venture in China, Bristol Myers Squibb is handing over its controlling stake in the business.BMS has inked an agreement to sell a 60% ownership stake in its China-based joint venture Sino-American Shanghai Squibb Pharmaceuticals (SASS), a BMS spokesperson told Fierce Pharma in an emailed statement. The move is primarily related to manufacturing of older medicines and consumer products in China and doesn't affect Bristol's core business in the country.An internal email circulating online suggests Hillhouse Capital is on the other end of the transaction. Hillhouse is one of Asia’s biggest investment firms, having invested in such biopharma outfits as BeOne Medicines (formerly BeiGene) and Jiangsu Hengrui Pharmaceuticals. The BMS spokesperson didn’t address the buyer’s identity. “As part of our long-term strategy, we continue to align our resources to support evolving business needs across our global network,” the BMS spokesperson said. “The planned sale of our interest in the SASS joint venture reflects the continued implementation of our manufacturing strategy—one that balances internal capabilities with strong external partnerships to enhance regional focus and ensure long-term supply reliability for patients in China and around the world.”BMS will work to assist any employees impacted by the deal and is prioritizing a “smooth and respectful transition” during the ownership change, the spokesperson added. BMS did not elaborate on the financial terms of the agreement.Crucially, the news does not mean that BMS’ core innovative drugs business will cease operation in China. BMS originally linked up with China’s Sinopharm Foreign Trade to establish SASS as the first U.S.-China pharmaceutical joint venture back in 1982. When China opened its economy to foreign entities in the 1980s, multinational corporations were only allowed to enter the country through joint ventures with state-owned, local companies such as Sinopharm.BMS’ China joint venture operates a 58,000-square-meter (roughly 624,307-square-foot) manufacturing facility in Shanghai responsible for production of antibiotics, cardiovascular drugs, analgesics and metabolic medicines, according to the company’s website.BMS’ stake sale isn’t expected to disrupt facility operations or product supply in China. The transaction includes both the sale of the joint venture itself and products that SASS makes exclusively for the mainland China market, including the hepatitis antiviral Baraclude, the buffered aspirin product Bufferin, the vitamin deficiency supplement Theragran, Monopril for high blood pressure and heart failure, and Velosef, which is an antibiotic used to treat bacterial infections. Several other prescription or over-the-counter medicines are listed under the joint venture, according to a database managed by China’s National Medical Products Administration.These days, as China has become more amenable to foreign entities’ participation in the domestic market, legacy joint ventures established by Western drugmakers often maintain a mix of older drug brands, off-patent medicines and consumer products separate from the companies’ innovative therapeutics businesses.Meanwhile, BMS isn’t the only ex-China drugmaker to dispense with certain legacy brands in the country. Last August, Belgium’s UCB said it was selling its mature neurology and allergy business in mainland China to local healthcare asset manager CBC Group and the Abu Dhabi-based investment organization Mubadala in a deal worth $680 million.The deal covered the divestment of seizure drugs Keppra and Vimpat, Neupro for Parkinson’s disease and restless leg syndrome, and the allergy meds Zyrtec and Xyzal, as well as a manufacturing facility in the city of Zhuhai, located in China’s Guangdong Province.The deal was designed, in part, to free up UCB’s focus on potential innovative medicine launches across immunology, neurology and rare diseases in China, the company’s CEO, Jean-Christophe Tellier, said at the time.

AcquisitionLicense out/in

02 Dec 2024

·www.pharmaindustrial-india.com

CBC Group Acquires UCB's Mature Product Portfolio in China

CBC Group has completed the acquisition of global biopharmaceutical company UCB's mature neurology and allergy business in China, in partnership with Mubadala Investment Company, the Abu Dhabi based global investment company. The acquisition marks another successful transaction under CBC's buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in China while expanding CBC's portfolio within the region's dynamic pharmaceutical market. The transaction, valued at USD 680 million, includes UCB's well-known brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and the Zhuhai manufacturing site. The well-established and trusted medicine portfolio will serve as an anchor asset as CBC builds out a leading integrated central nervous system (CNS) biopharma platform in China, where the market size has reached USD 33 billion. Beyond strengthening CBC's presence in the rapidly growing Chinese healthcare market, the acquisition also enhances the firm's capabilities in meeting the rising demand for neurology and allergy treatments in the wider region. In collaboration with Mubadala, CBC will tap on its proprietary investor-operator approach, deep healthcare expertise and platform synergies to drive operational efficiencies, innovation and scale to benefit more patients across the region. Fu Wei, Chief Executive Officer of CBC Group, said, "There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today's healthcare investing market. Together, we are making a profound impact on the industry by harnessing our combined expertise and capital to not only enhance patient outcomes but also build value for our stakeholders. Leveraging our joint strengths, we are poised to capitalize on synergies and deploy hands-on strategic guidance to make significant strides in CNS market access and innovation." Named 'NeuroGen Pharma', the new company embodies what CBC and Mubadala envision for neuro healthcare innovation. The company will be led by a deep and experienced management team with an extensive track record in the biopharma industry, ensuring a smooth transition to propel it into the next phase of growth. NeuroGen Pharma is expected to deliver quality treatments to a wider reach of patients and play an important role in addressing the evolving neurology treatment needs in China. The company aims to leverage innovative therapies and cutting-edge research to enhance patient outcomes and shape the future of neurology care in the region. Combined net sales for the acquired portfolio in this transaction were Euro131 million in 2023. The strategic acquisition builds on CBC's collaboration with Mubadala, which includes their investment in CBC Healthcare Infrastructure Platform's (HIP) first life science real assets venture and the joint investment in the USD 315 million fundraising round for CBC-backed Hasten, a leading pharmaceutical company. Mohamed Albadr, Head of Asia at Mubadala, said, "We are thrilled to partner with CBC Group to support the growth and development of NeuroGen Pharma as it scales to a leading entity in China and delivers transformative medicines to patients. Built on a strong foundation of proven therapies and driven by innovation and cutting-edge research, the company is uniquely positioned to address the growing need for advanced neurology and allergy treatments while aligning with our commitment to enhancing access to care and growth in the healthcare system." Jean-Christophe Tellier, CEO at UCB, said, "In the short term, UCB is exploring the launch of novel medicines in immunology, neurology, and rare diseases in China. Our dedication to serving patients with unmet needs in China remains steadfast. Building on our 28-year presence in the country, we are committed to driving patient outcomes through continued collaboration with local partners and fostering innovation. We are convinced that the CBC Group and Mubadala are the ideal partners to advance the medicine portfolio and continue to improve the lives of people living with neurology and allergy diseases in mainland China."

Acquisition

02 Dec 2024

·www.pharmaceutical-technology.com

CBC acquires UCB’s neurology and allergy business in China

The new company aims to deliver quality treatments and address evolving neurology treatment needs in the country. Credit: Volha_R/Shutterstock. CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge’s ( UCB ) mature neurology and allergy business in China for $680m. The move comes after UCB agreed to sell and license its business in August 2024. The deal encompasses UCB’s Zhuhai manufacturing site and its brands Xyzal, Keppra, Zyrtec, Vimpat and Neupro. They are set to be the cornerstone assets for CBC as it develops an integrated central nervous system (CNS) biopharma platform in China. Working alongside Mubadala, CBC plans to leverage its platform synergies, investor-operator approach and healthcare expertise, to optimise operations, foster innovation and expand its reach to benefit more patients in the region. The new entity formed from this acquisition called NeuroGen Pharma is set to offer neuro healthcare innovation services. It will be spearheaded by a management team with a solid background in the biopharma industry, which is expected to ensure a seamless transition and drive future growth. The company aims to deliver quality treatments and address the evolving neurology treatment needs in the country. The acquired portfolio reported combined net sales of €131m ($138m) in 2023. The strategic acquisition is part of a broader partnership between CBC and Mubadala, which also includes their joint investment in the $315m fundraising round for Hasten and an investment in CBC Healthcare Infrastructure Platform’s first life science real assets venture. CBC Group CEO Fu Wei stated: “There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. “This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today’s healthcare investing market.”

Acquisition

100 Deals associated with Rotigotine

External Link

KEGG	Wiki	ATC	Drug Bank
D05768	Rotigotine	N04BC09	DB05271

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parkinson Disease	European Union	UCB Pharma SA	15 Feb 2006
Parkinson Disease	Iceland	UCB Pharma SA	15 Feb 2006
Parkinson Disease	Liechtenstein	UCB Pharma SA	15 Feb 2006
Parkinson Disease	Norway	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	European Union	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	Iceland	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	Liechtenstein	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	Norway	UCB Pharma SA	15 Feb 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Parkinson's disease	Phase 3	China	Shandong Luye Pharmaceutical Co., Ltd.	03 Feb 2020
Kidney Failure, Chronic	Phase 3	United States	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Austria	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Finland	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	France	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Germany	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Italy	UCB BioSciences GmbH	01 Apr 2012
Gastrointestinal dysfunction	Phase 3	United States	UCB Pharma GmbH	01 Jan 2012
Dyssomnias	Phase 3	Germany	UCB Pharma GmbH	01 Nov 2004
Young onset Parkinson disease	Phase 3	Australia	UCB Pharma GmbH	01 Aug 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MDS2025	Phase 3	Parkinson Disease	294	LY03003	bbwoknsimo(djnkcazjcq) = ddrrekrjtv tcpeeooblh (nqwpkpqyec ) View more	Positive	05 Oct 2025
				Placebo	bbwoknsimo(djnkcazjcq) = updkltddeu tcpeeooblh (nqwpkpqyec ) View more
NCT03992196 (CTgov)	Phase 3	Restless Legs Syndrome	10	Rotigotine (Rotigotine Final Dose 2 mg/24 h)	jjyxvhxhwa = ikbzbfooxv jhiytteflh (fcxassisgx, wfvpqxlhqf - noqyoatpuw) View more	-	30 Oct 2023
				Rotigotine (Rotigotine Final Dose 3 mg/24 h)	jjyxvhxhwa = ppqvshllmy jhiytteflh (fcxassisgx, htgmsdhbkh - xmucinbakf) View more
NCT03728933 (CTgov)	Phase 3	Restless Legs Syndrome	23	Placebo	vrfhgfkpho(ftdvvkdixq) = dapnnrnsqk bftcyrgevs (ebnjqdjlds, 6.8) View more	-	26 Oct 2023
NCT04937452 (CTAD2023)	Phase 2	Frontotemporal Dementia	75	Rotigotine 4 mg/day	xqyjozzzob(nsvmrmkqnv) = xomzykjgxi dafjabwjfm (duryhoaexk, −0.669 - 1.037)	Negative	24 Oct 2023
				Rotigotine 6 mg/day	xqyjozzzob(nsvmrmkqnv) = epwjfjdjnt dafjabwjfm (duryhoaexk, − 0.225 - 1.037)
NCT04571164 (NEWS) Manual	Phase 3	Parkinson Disease	294	LY03003	lggnvwuqwl(wqnsaeohch) = ，與安慰劑組相比，LY 03003組統一帕金森病評分量表(UPDRS)Ⅱ+Ⅲ評分較基綫顯著改善，兩組差異具有統計學意義（ P＜0.001 ）。 mtihvenyvk (rnudauqdyi ) View more	Positive	19 Jul 2022
				Placebo
NCT02365870 (ANXPD, CTgov)	Phase 4	Anxiety Disorders \| Parkinson Disease	4	rotigotine transdermal patch (Rotigotine)	yisixmpcew(nyaupntbla) = pvzuqtlbnm zduujlvowe (mfzuwguqsc, 0) View more	-	19 Mar 2020
				placebo (Placebo)	yisixmpcew(nyaupntbla) = kfqaatooqd zduujlvowe (mfzuwguqsc, 5.1) View more
NCT03103919 (CTgov)	Phase 4	Parkinson Disease, Secondary \| Parkinson Disease	40	Kinesia-ONE™+Rotigotine (Rotigotine + Standard Care)	hteqvpsvsw(naxxeyuvbc) = yroecqvbma ahzotalnhe (wbwmosswdj, zfiwonsakk - ivntdfmike) View more	-	19 Feb 2019
				Kinesia-360™+Rotigotine (Rotigotine + Standard Care + Kinesia-360™ Wearable Device)	hteqvpsvsw(naxxeyuvbc) = xyhcgbywpu ahzotalnhe (wbwmosswdj, erwxkfujpc - ywtiuuvknl) View more
NCT02230904 (PD0018, Pubmed \| Curr Med Res Opin) Manual	Phase 1	Parkinson Disease	57	rotigotine (Treatments A)	lfdgrtgmyo(wgosyqtehv) = hyaimceqot vlixaixnml (uhtnuwrlvx, 1.635) View more	Positive	01 Jul 2018
				rotigotine (Treatments B)	wyoxifvgcb(ikoncjnjky) = nnekffmshu znupbnslhh (gdxdsnlpjp )
NCT01646255 (SP1037, Pubmed \| Parkinsonism Relat Disord 1 \| Parkinsonism Relat Disord 2) Manual	Phase 3	Parkinson Disease	346	Rotigotine	gccdovrdfn(dbribikncv): difference = -1.20 (95% CI, -1.83 to -0.57), P-Value = 0.0002 View more	Positive	01 Nov 2017
				Placebo
NCT01495793 (Pubmed \| Sleep Med)	Phase 2	Restless Legs Syndrome	24	Rotigotine transdermal system 0.5 mg/24 h	ssvwuoxdrj(onkiqtwdwd) = jobqxywndh juwztigbht (iambccmeqg ) View more	-	01 Apr 2017
				Rotigotine transdermal system 1 mg/24 h	ssvwuoxdrj(onkiqtwdwd) = ojuapuznmz juwztigbht (iambccmeqg ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rotigotine

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation